Disc Medicine to pursue traditional U.S. approval after FDA rejects new fast-track route

Disc to pursue traditional U.S. approval for bitopertin after FDA rejects new fast-track route | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly//File Photo [Purchase Licensing Rights, opens new tab]- Companies[Disc Medicine Inc]FollowFeb 17 (Reuters) - Disc Medicine [(IRON.O), opens new t ...